BGI

BGI, as the founder of China's genomics industry, adheres to the vision of "Genomic science for the benefit of humanity." With over 20 years of talent accumulation, scientific research, and industrial development, BGI has built a marketing and service network covering more than 100 countries worldwide and all provinces, autonomous regions, and municipalities in China. It has become one of the few technology companies in the industry that spans the entire industrial chain and all application fields. Based on its advanced multi-omics production platform equipped with cutting-edge technology, comprehensive configurations, and leading scale, BGI is now one of the world’s leading providers of scientific and technological services and precision medicine operators. The company's main business involves providing research services and integrated precision medical testing solutions to research institutions, enterprises, medical institutions, and public health organizations through multi-omics big data technologies such as genetic testing, mass spectrometry detection, and bioinformatics analysis. BGI aims to advance life science research, promote the application of life big data, and improve global healthcare standards. Leveraging genomic research achievements and precision detection technologies for public health applications, BGI is committed to accelerating technological innovation, reducing birth defects, strengthening cancer prevention and control, mitigating the impact of major diseases on humanity, achieving precise treatment of infections, and comprehensively supporting precision medicine. Headquartered in Shenzhen, China, BGI has branches and medical testing laboratories in major Chinese cities such as Beijing, Tianjin, Wuhan, Shanghai, and Guangzhou. It also operates overseas centers and core laboratories in Hong Kong, Europe, the Americas, and the Asia-Pacific region, forming a "China-wide coverage, globally connected" network layout. Its services reach over 100 countries and regions worldwide, including more than 2,000 research institutions and 2,300 medical institutions in China, among which are over 500 tertiary hospitals. BGI collaborates with over 3,000 overseas medical and research institutions in Europe, the Americas, and the Asia-Pacific region and has established partnerships with health authorities in more than 30 countries and regions.